Latest news
Iconovo launches improved versions of nasal ICOone inhalers
Iconovo launches improved versions of nasal ICOone. Both inhalers are designed for high technical performance and to minimize the risk of user error.…
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler
Iconovo announces that it has received an order from a company revenue wise ranking among the top ten largest pharma companies in the world to evaluate…
Press releases
Apr 15, 2020, 09:40
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 08, 2020, 16:15
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 07, 2020, 10:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 27, 2020, 15:18
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 20, 2020, 09:15
News
IR
Swedish
Regulatory
Corporate Information
Other Corporate Information
Mar 19, 2020, 14:18
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 13, 2020, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 11, 2020, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Feb 14, 2020, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 10, 2020, 19:39
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Jan 10, 2020, 08:22
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se